



ISSN 0975-413X
CODEN (USA): PCHHAX

Der Pharma Chemica, 2016, 8(9):112-117
(<http://derpharmacemica.com/archive.html>)

Dehydration of 1,2,3-triaryl-3-hydroxy-1-propanones: An alternative route for synthesis of triaryl-2-propen-1-ones

Viwat Hahnajanawong*, Baramee Pungpis and Parinya Theramongkol

Natural Products Research Unit, Department of Chemistry and Center for Innovation in Chemistry, Faculty of Science, Khon Kaen University, Khon Kaen 40002, Thailand

ABSTRACT

N-Heterocyclic carbene-catalyzed reaction of aromatic aldehydes with benzyl halides leads to formation of 1,3-diaryl-3-hydroxy-2-phenylpropan-1-ones. Subsequent dehydration offers a route to 1,3-diaryl-2-phenyl-2-propen-1-ones.

Key words: *N-heterocyclic carbene, benzyl halides, [bmim]OH, 1,2,3-triaryl-2-propen-1-ones*

INTRODUCTION

(E)- and (Z)-1,2,3-Triaryl-2-propen-1-ones obtained from aldol condensation of aryl benzyl ketone have been reported to possess potency and selectivity on COX-2 inhibition [1]. Apart from Friedel-Craft acylation of benzene derivatives with phenylacetyl chloride in the presence of AlCl₃, the *N*-heterocyclic carbenes (NHCs) catalyzed cross-coupling of aromatic aldehydes with benzyl halides is an alternative route for producing aryl benzyl ketones [2]. As we are interested in catalytic activity of NHC generated from *N,N*-dimethylbenzimidazolium iodide [3-5] and the employment of the basic ionic liquid [bmim]OH as reaction medium and base [6-10], herein we report the synthesis of triaryl propenones *via* aldol condensation of aryl benzyl ketones obtained from treatment of aromatic aldehydes with benzyl halides in the presence of *N,N*-dimethylbenzimidazolium iodide in [bmim]OH.

MATERIALS AND METHODS

Solvents were purified according to standard methods prior to use, while all other chemicals used were commercially available and used as received. Melting points were measured using a Sanyo Gallenkamp melting point apparatus and are uncorrected. IR spectra were recorded on a Perkin Elmer Spectrum One FT-IR Spectrometer. ¹H and ¹³C NMR spectra were recorded using a VARIAN MERCURY plus (400 MHz FT NMR). *N,N*-Dimethylbenzimidazolium iodide was prepared following our previously reported procedure [11].

General procedure for the cross-coupling of aromatic aldehydes with benzyl halides

To a stirred solution of *N,N*-dimethylbenzimidazolium iodide (**3**) (0.137 g, 0.5 mmol) in [bmim]OH (3.0 ml) was added an aromatic aldehyde (1.0 mmol) and a benzyl halide (2.0 mmol) at room temperature. After 8-16 hours, the completion of the reaction was indicated by TLC (10% ethyl acetate/hexane), the reaction mixture was extracted with ethyl acetate (3 × 30 ml). The combined organic layers were dried (anh.Na₂SO₄) and the solvent was removed under reduced pressure. The residue was purified by using preparative thin layer chromatography with 10% ethyl acetate /hexane as eluent to afford the 1,3-diaryl-3-hydroxy-2-phenylpropan-1-one, aroin and benzyl ester.

3-Hydroxy-1,2,3-triphenylpropan-1-one (4a)

White crystals; mp 119-120 °C; IR (KBr) (v): 3507, 3053, 3026, 1676, 1595, 1445, 1215, 699 cm⁻¹; ¹H NMR (CDCl₃) δ: 7.70 (2H, d, *J* = 7.6 Hz, 2'-*H* and 6'-*H*), 7.52 (2H, d, *J* = 7.6 Hz, 2'''-*H* and 6'''-*H*), 7.37-7.45 (3H, m, Ar-*H'*), 7.23-7.34 (3H, m, Ar-*H'''*), 7.16-7.17 (3H, m, Ar-*H''*), 6.94-6.96 (2H, m, Ar-*H''*), 4.03 (1H, s, OH), 3.78 (1H, d, *J* = 13.6 Hz, 2-*H*), 3.52 (1H, d, *J* = 13.6 Hz, 3-*H*); ¹³C NMR (CDCl₃) δ: 44.9, 82.2, 125.9, 127.0, 128.1, 128.9, 130.2, 130.4, 130.6, 130.7, 132.8, 134.7, 135.1, 142.0, 200.6.

1,3-Di(4-chlorophenyl)-3-hydroxy-2-phenylpropan-1-one (4b)

Yellow crystals; mp 103-104 °C; IR (KBr) (v): 3458, 3064, 2925, 2852, 1678, 1587, 1457, 1210, 702 cm⁻¹; ¹H NMR (CDCl₃) δ: 7.70 (2H, d, *J* = 8.4 Hz, 2'-*H* and 6'-*H*), 7.43 (2H, d, *J* = 8.4 Hz, 3'-*H* and 5'-*H*), 7.36 (2H, d, *J* = 8.8 Hz, 3'''-*H* and 5'''-*H*), 7.27 (2H, d, *J* = 8.4 Hz, 2'''-*H* and 6'''-*H*), 7.20-7.21 (3H, m, Ar-*H''*), 6.96-6.98 (2H, m, Ar-*H''*), 3.73 (1H, d, *J* = 13.6 Hz, 2-*H*), 3.68 (1H, s, OH), 3.40 (1H, d, *J* = 13.6 Hz, 3-*H*); ¹³C NMR (CDCl₃) δ: 45.5, 82.1, 127.0, 127.4, 128.4, 128.5, 129.1, 130.7, 131.7, 132.8, 134.2, 134.5, 139.5, 140.3, 198.9.

1,3-Di(4-fluorophenyl)-3-hydroxy-2-phenylpropan-1-one (4c)

White crystals; mp 98-100 °C; IR (KBr) (v): 3466, 3068, 3032, 2928, 1679, 1598, 1454, 1232, 1158, 1091, 702 cm⁻¹; ¹H NMR (CDCl₃) δ: 7.78 (2H, dd, *J* = 8.8 Hz and 5.6 Hz, 2'-*H* and 6'-*H*), 7.47 (2H, dd, *J* = 8.4 Hz and 5.2 Hz, 2'''-*H* and 6'''-*H*), 7.20-7.21 (3H, m, Ar-*H''*), 7.09 (2H, t, *J* = 8.8 Hz, 3'-*H* and 5'-*H*), 6.95-7.01 (4H, m, Ar-*H''* and Ar-*H'''*), 3.82 (1H, s, OH), 3.74 (1H, d, *J* = 13.6 Hz, 2-*H*), 3.45 (1H, d, *J* = 13.6 Hz, 3-*H*); ¹³C NMR (CDCl₃) δ: 45.5, 82.0, 115.3, 115.5, 115.8, 116.0, 127.3, 127.4, 127.5, 128.4, 130.6, 130.8, 130.9, 133.1, 133.2, 134.6, 137.6, 137.7, 161.2, 163.7, 164.1, 166.6, 198.7.

3-Hydroxy-2-phenyl-1,3-di-p-tolylpropan-1-one (4d)

White crystals; mp 111-112 °C; IR (KBr) (v): 3435, 3032, 2925, 2863, 1669, 1504, 1300, 1179, 1092, 820 cm⁻¹; ¹H NMR (CDCl₃) δ: 7.63 (2H, d, *J* = 8.4 Hz, 2'-*H* and 6'-*H*), 7.39 (2H, d, *J* = 8.4 Hz, 5'-*H* and 3'-*H*), 7.19 (2H, d, *J* = 8.0 Hz, 2'''-*H* and 6'''-*H*), 7.14-7.17 (3H, m, Ar-*H''*), 7.11 (2H, d, *J* = 8.4 Hz, 3'''-*H* and 5'''-*H*), 6.94-6.96 (2H, m, Ar-*H''*), 4.23 (1H, s, OH), 3.76 (1H, d, *J* = 13.2 Hz, 2-*H*), 3.56 (1H, d, *J* = 13.6 Hz, 3-*H*), 2.35 (3H, s, Ar-CH₃), 2.34 (3H, s, Ar-CH₃); ¹³C NMR (CDCl₃) δ: 21.1, 21.6, 44.7, 81.8, 125.8, 126.9, 128.0, 128.9, 129.5, 130.5, 130.6, 132.0, 135.3, 137.8, 139.4, 143.6, 200.2.

3-Hydroxy-1,3-di-(4-methoxyphenyl)-2-phenylpropan-1-one (4e)

Yellow crystals; mp 91-92 °C; IR (KBr) (v): 3458, 3064, 3031, 2925, 2852, 1678, 1587, 1454, 1249, 1210, 1093, 702 cm⁻¹; ¹H NMR (CDCl₃) δ: 7.95 (2H, d, *J* = 8.8 Hz, 2'-*H* and 6'-*H*), 7.74 (2H, d, *J* = 8.8 Hz, 2'''-*H* and 6'''-*H*), 7.42 (2H, d, *J* = 8.8 Hz, 3'-*H* and 5'-*H*), 7.16 (2H, d, *J* = 6.4 Hz, 2''-*H* and 6''-*H*), 6.91-6.98 (3H, m, Ar-*H''*), 6.79 (2H, d, *J* = 8.8 Hz, 3'''-*H* and 5'''-*H*), 4.36 (1H, s, OH), 3.89 (3H, s, Ar-OCH₃), 3.82 (3H, s, Ar-OCH₃), 3.73 (1H, d, *J* = 13.2 Hz, 2-*H*), 3.58 (1H, d, *J* = 13.6 Hz, 3-*H*); ¹³C NMR (CDCl₃) δ: 44.7, 55.3, 55.4, 81.3, 113.5, 114.3, 127.3, 128.0, 130.6, 132.4, 132.8, 134.7, 135.3, 159.3, 163.2, 164.9, 198.9.

Benzoin (5a)

White crystals; mp 134-136 °C; IR (KBr) (v): 3413, 3058, 3027, 2931, 1678, 1595, 1449, 1262, 1206, 755 cm⁻¹; ¹H NMR (CDCl₃) δ: 7.91 (2H, d, *J* = 7.6 Hz, 2-*H* and 6-*H*), 7.52 (1H, t, *J* = 7.6 Hz, 4-*H*), 7.39 (2H, t, *J* = 7.6 Hz, 3-*H* and 5-*H*), 7.26-7.33 (5H, m, Ar-*H*), 5.95 (1H, s, CH), 4.54 (1H, br s, OH); ¹³C NMR (CDCl₃) δ: 76.2, 127.8, 128.6, 128.7, 129.1, 133.5, 133.9, 139.0, 198.9.

4,4'-Dichlorobenzoin (5b)

White crystals; mp 87-88 °C; IR (KBr) (v): 3425, 3072, 2929, 1674, 1590, 1488, 1401, 1252, 1207, 1093 cm⁻¹; ¹H NMR (CDCl₃) δ: 7.75 (2H, d, *J* = 8.4 Hz, 2-*H* and 6-*H*), 7.32 (2H, d, *J* = 8.4 Hz, 3-*H* and 5-*H*), 7.24 (2H, d, *J* = 8.4 Hz, 3'-*H* and 5'-*H*), 7.18 (2H, d, *J* = 8.4 Hz, 2'-*H* and 6'-*H*), 5.81 (1H, s, CH); ¹³C NMR (CDCl₃) δ: 77.3, 129.1, 129.2, 129.4, 130.4, 131.6, 134.8, 137.2, 140.7, 197.5.

4,4'-Difluorobenzoin (5c)

White crystals; mp 81-82 °C; IR (KBr) (v): 3450, 3074, 2927, 1676, 1596, 1506, 1231, 1156, 838 cm⁻¹; ¹H NMR (CDCl₃) δ: 7.93 (2H, dd, *J* = 8.8 Hz and 5.2 Hz, 2-*H* and 6-*H*), 7.30 (2H, dd, *J* = 8.8 Hz and 5.2 Hz, 2'-*H* and 6'-*H*), 7.08 (2H, t, *J* = 8.8 Hz, 3-*H* and 5-*H*), 7.02 (2H, t, *J* = 8.4 Hz, 3'-*H* and 5'-*H*), 5.90 (1H, s, CH), 4.54 (1H, br s, OH); ¹³C NMR (CDCl₃) δ: 75.3, 116.0, 116.1, 116.2, 116.3, 129.4, 129.5, 129.6, 129.7, 131.8, 131.9, 134.7, 134.8, 161.5, 164.0, 164.8, 167.4, 197.2.

4,4'-Dimethylbenzoin (5d)

White crystals; mp 73-75 °C; IR (KBr) (v): 3448, 3030, 2921, 1673, 1607, 1512, 1448, 1387, 1178 cm⁻¹; ¹H NMR (CDCl₃) δ: 7.81 (2H, d, *J* = 8.4 Hz, 2-H and 6-H), 7.21 (2H, d, *J* = 8.4 Hz, 3-H and 5-H), 7.18 (2H, d, *J* = 8.0 Hz, 2'-H and 6'-H), 7.11 (2H, d, *J* = 8.0 Hz, 3'-H and 5'-H), 5.89 (1H, s, CH), 2.35 (3H, s, Ar-CH₃), 2.28 (3H, s, Ar-CH₃); ¹³C NMR (CDCl₃) δ: 21.1, 21.7, 75.8, 127.6, 129.3, 129.4, 129.8, 131.0, 136.4, 138.3, 144.9, 198.5.

4,4'-Dimethoxybenzoin (5e)

White crystals; mp 104-106 °C; IR (KBr) (v): 3454, 3005, 2936, 2839, 1668, 1598, 1462, 1307, 1252, 1170 cm⁻¹; ¹H NMR (CDCl₃) δ: 7.89 (2H, d, *J* = 8.8 Hz, 2-H and 6-H), 7.24 (2H, d, *J* = 8.8 Hz, 3-H and 5-H), 6.85 (2H, d, *J* = 6.0 Hz, 2'-H and 6'-H), 6.83 (2H, d, *J* = 6.0 Hz, 3'-H and 5'-H), 5.85 (1H, s, CH), 3.81 (3H, s, Ar-OCH₃), 3.74 (3H, s, Ar-OCH₃); ¹³C NMR (CDCl₃) δ: 55.2, 55.5, 75.2, 113.9, 114.5, 126.3, 129.0, 131.6, 131.8, 159.6, 164.0, 197.3.

Benzyl benzoate (6a)

Yellow liquid; IR (neat) (v): 3065, 3034, 2953, 2890, 1721, 1602, 1585, 1452, 1377, 1272, 712 cm⁻¹; ¹H NMR (CDCl₃) δ: 8.08 (2H, d, *J* = 7.6 Hz, 2-H and 6-H), 7.55 (1H, t, *J* = 7.6 Hz, 4-H), 7.44 (4H, m, Ar-H), 7.39 (2H, t, *J* = 8.4 Hz, 3'-H and 5'-H), 7.35 (1H, t, *J* = 8.4 Hz, 4'-H), 5.37 (2H, s, CH₂); ¹³C NMR (CDCl₃) δ: 66.7, 128.1, 128.2, 128.4, 128.6, 129.7, 130.2, 133.0, 136.1, 166.4.

Benzyl 4-chlorobenzoate (6b)

Yellow liquid; IR (neat) (v): 3035, 2957, 2929, 1721, 1645, 1595, 1488, 1456, 1270, 758 cm⁻¹; ¹H NMR (CDCl₃) δ: 8.01 (2H, d, *J* = 8.4 Hz, 2-H and 6-H), 7.39 (7H, m, Ar-H), 5.36 (1H, s, CH₂); ¹³C NMR (CDCl₃) δ: 67.0, 128.3, 128.4, 128.6, 128.7, 129.0, 131.1, 135.8, 139.5, 165.6.

Benzyl 4-fluorobenzoate (6c)

White liquid; IR (neat) (v): 3068, 3035, 2956, 1724, 1603, 1505, 1456, 1378, 1270, 1238, 1111, 766, 696 cm⁻¹; ¹H NMR (CDCl₃) δ: 8.01 (2H, dd, *J* = 8.8 Hz and 5.6 Hz, 2-H and 6-H), 7.44 (2H, d, *J* = 6.8 Hz, 2'-H and 6'-H), 7.34-7.41 (3H, m, Ar-H'), 7.09 (2H, t, *J* = 8.8 Hz, 3-H and 5-H), 5.35 (1H, s, CH₂); ¹³C NMR (CDCl₃) δ: 66.9, 115.4, 115.6, 126.4, 126.5, 128.2, 128.3, 128.6, 132.2, 132.3, 135.9, 164.6, 165.5, 167.1.

Benzyl 4-methylbenzoate (6d)

Colorless liquid; IR (neat) (v): 3091, 3055, 2986, 2958, 1717, 1613, 1455, 1272 cm⁻¹; ¹H NMR (CDCl₃) δ: 7.97 (2H, d, *J* = 8.0 Hz, 2-H and 6-H), 7.44 (2H, d, *J* = 7.6 Hz, 2'-H and 6'-H), 7.45 (2H, d, *J* = 7.2 Hz, 3'-H and 5'-H), 7.35 (1H, t, *J* = 7.2 Hz, 4'-H), 7.23 (2H, d, *J* = 8.0 Hz, 3-H and 5-H), 5.35 (2H, s, CH₂), 2.40 (3H, s, Ar-CH₃); ¹³C NMR (CDCl₃) δ: 21.7, 66.5, 127.4, 128.1, 128.2, 128.6, 129.1, 129.7, 136.2, 143.7, 166.5.

Benzyl 4-methoxybenzoate (6e)

Colorless liquid; IR (neat) (v): 3091, 3055, 2986, 2958, 1717, 1613, 1455, 1272 cm⁻¹; ¹H NMR (CDCl₃) δ: 7.97 (2H, d, *J* = 8.0 Hz, 2-H and 6-H), 7.44 (2H, d, *J* = 7.2 Hz, 2'-H and 6'-H), 7.45 (2H, d, *J* = 7.2 Hz, 3'-H and 5'-H), 7.35 (1H, t, *J* = 7.2 Hz, 4'-H), 7.23 (2H, d, *J* = 8.0 Hz, 3-H and 5-H), 5.35 (2H, s, CH₂), 2.40 (3H, s, Ar-CH₃); ¹³C NMR (CDCl₃) δ: 21.7, 66.5, 127.4, 128.1, 128.2, 128.6, 129.1, 129.7, 136.2, 143.7, 166.5.

General procedure for dehydration of 1,2,3-triaryl-3-hydroxy-1-propanones

A mixture of an appropriate 1,2,3-triaryl-3-hydroxy-1-propanone (1.0 mmol) and P₂O₅ (2.0 mmol) in benzene (25 ml) was refluxed for 12-16 hours. The benzene layer was decanted and the residue was washed once with hot benzene. The combined benzene layers were washed with water, dried (anh.Na₂SO₄) and concentrated under reduced pressure. The residue was purified by using preparative thin layer chromatography with 100% dichloromethane as eluent to afford the corresponding 1,3-diaryl-2-phenyl-2-propen-1-one.

1,2,3-Triphenylprop-2-en-1-one (20a)

White crystals; mp 108-109 °C; IR (KBr) (v): 3057, 3028, 2923, 2857, 1687, 1666, 1595, 1484, 1270, 1090 cm⁻¹; ¹H NMR (CDCl₃) δ: 8.00 (2H, d, *J* = 7.2 Hz, 2'-H and 6'-H), 7.47 (2H, d, *J* = 8.8 Hz, 2''-H and 6''-H), 7.34-7.38 (5H, m, Ar-H), 7.28-7.31 (4H, m, Ar-H), 7.20 (1H, s, CH), 7.18 (2H, d, *J* = 7.6 Hz, 2'''-H and 6'''-H); ¹³C NMR (CDCl₃) δ: 122.1, 126.3, 128.5, 128.6, 128.9, 129.0, 129.7, 130.3, 131.6, 133.9, 134.4, 136.1, 137.7, 141.7, 199.1.

1,3-Di-(4-chlorophenyl)-2-phenylprop-2-en-1-one (20b)

White crystals; mp 96-97 °C; IR (KBr) (v): 3060, 3030, 2924, 2857, 1654, 1591, 1493, 1448, 1252, 1067 cm⁻¹; ¹H NMR (CDCl₃) δ: 7.89 (2H, d, *J* = 8.4 Hz, 2'-H and 6'-H), 7.78 (2H, d, *J* = 8.4 Hz, 2''-H and 6''-H), 7.43 (2H, d, *J* = 8.4 Hz, 2'''-H and 6'''-H), 7.36 (1H, s, CH), 7.31-7.35 (3H, m, Ar-H), 7.24-7.26 (2H, m, Ar-H), 7.18-7.21 (2H, m,

Ar-H); ^{13}C NMR (CDCl_3) δ : 122.6, 127.6, 129.2, 129.4, 130.2, 131.0, 131.7, 131.8, 133.9, 134.3, 134.7, 135.8, 140.0, 140.7, 197.4.

1,3-Di-(4-fluorophenyl)-2-phenylprop-2-en-1-one (20c)

White crystals; mp 113-114 °C; IR (KBr) (v): 3064, 3027, 2924, 2852, 1689, 1661, 1598, 1504, 1451, 1229, 1157 cm^{-1} ; ^1H NMR (CDCl_3) δ : 7.38 (2H, dd, $J = 8.4$ Hz and 5.6 Hz, 2'-H and 6'-H), 7.19-7.23 (3H, m, Ar-H), 7.10-7.17 (5H, m, Ar-H and CH), 7.05 (2H, dd, $J = 8.8$ Hz and 5.6 Hz, 2''-H and 6''-H), 6.78 (2H, t, $J = 8.8$ Hz, 3''-H and 5''-H); ^{13}C NMR (CDCl_3) δ : 114.9, 115.1, 115.7, 116.0, 120.3, 124.0, 125.9, 126.8, 127.0, 128.1, 128.7, 130.7, 130.8, 131.1, 131.2, 139.4, 144.6, 148.0, 160.4, 161.0, 162.8, 163.5, 198.2.

2-Phenyl-1,3-di-p-tolylprop-2-en-1-one (20d)


Yellow liquid; IR (neat) (v): 3052, 3025, 2920, 2863, 1659, 1603, 1571, 1447, 1254, 1172 cm^{-1} ; ^1H NMR (CDCl_3) δ : 7.91 (2H, d, $J = 7.6$ Hz, 2'-H and 6'-H), 7.37 (2H, d, $J = 8.0$ Hz, 2''-H and 6''-H), 7.31 (2H, d, $J = 7.2$ Hz, 2'''-H and 6'''-H), 7.15-7.21 (8H, m, Ar-H, CH), 2.34 (6H, s, 2(Ar-CH₃)); ^{13}C NMR (CDCl_3) δ : 21.1, 21.7, 126.2, 127.7, 128.4, 128.7, 128.8, 129.4, 129.5, 129.8, 134.0, 135.3, 135.6, 138.1, 141.0, 141.5, 199.0.

1,3-Di(4-methoxyphenyl)-2-phenylprop-2-en-1-one (20e)

Colorless liquid; IR (neat) (v): 3058, 3008, 2958, 2840, 1652, 1594, 1505, 1454, 1251, 1163 cm^{-1} ; ^1H NMR (CDCl_3) δ : 7.97 (2H, d, $J = 8.8$ Hz, 2'-H and 6'-H), 7.40 (2H, d, $J = 8.8$ Hz, 2''-H and 6''-H), 7.29 (2H, d, $J = 7.2$ Hz, 2'''-H and 6'''-H), 7.13-7.20 (3H, m, Ar-H), 7.07 (1H, s, CH), 6.87 (2H, d, $J = 8.8$ Hz, 3'-H and 5'-H), 6.83 (2H, d, $J = 8.8$ Hz, 3''-H and 5''-H), 3.80 (3H, s, Ar-CH₃), 3.79 (3H, s, Ar-CH₃); ^{13}C NMR (CDCl_3) δ : 55.3, 55.4, 114.0, 114.2, 127.5, 127.6, 127.7, 128.4, 128.7, 129.6, 130.7, 132.1, 135.7, 140.5, 159.6, 163.9, 195.1.


RESULTS AND DISCUSSION

Carrying out cross-coupling of aromatic aldehydes **1a-e** with 2 equivalents of benzyl chloride (**2a**) in the presence of 50 mol% of *N,N*-dimethylbenzimidazolium iodide (**3**) in [bmim]OH without additional hydroxide base at room temperature produced corresponding 1,3-diaryl-3-hydroxy-2-phenylpropan-1-ones **4a-e** in 50-83% yields as shown in Scheme 1. Additionally, aroins **5a-e** and benzyl esters **6a-e** were also obtained as side products in 4-17% yields and in 3-4 % yields respectively. Employment of benzyl bromide (**2b**) instead of benzyl chloride (**2a**) afforded the same products in similar yields.




Scheme 1 Products from coupling of aromatic aldehydes with benzyl halides

Our plausible mechanistic pathway responsible for the formation of 1,3-diaryl-3-hydroxy-2-phenylpropan-1-ones **4a-e** is illustrated in Scheme 2. Accordingly, *N,N*-dimethylbenzimidazol-2-ylidene (**7**) generated *in situ* from deprotonation of benzimidazolium salt **3** reacts with aromatic aldehyde **1** to give the Breslow intermediate **9** which then reacts with benzyl halide **2** to give aryl benzyl ketone **11**. Deprotonation of **11** follows by addition of the enolate anion **12** to aromatic aldehyde **1** produces 1,3-diaryl-3-hydroxy-2-phenylpropan-1-one **4**.



Scheme 2 Proposed mechanism for the formation of 3-hydroxy-1,2,3-triarylpropan-1-ones 4




Scheme 3 Proposed mechanism for the formation of benzyl esters 6

Aroins **5a-e** were obtained from benzoin condensation. Benzyl esters **6a-e** probably occurred through the mechanism involving oxygenation with molecular oxygen. As illustrated in Scheme 3, intermediate **8** reacts with benzyl halide **2** to give a benzyl ether **13**. Deprotonation of **13** gives enol ether **14** which undergoes oxygenation to give peroxy radical **15**. Subsequent coupling with another equivalent of **14** provides peroxide **16**. Homolytic

cleavage and intramolecular coupling of the diradical **17** gives epoxide **18** which is then subjected to epoxide ring opening to give esters **6a-e** after the departure of benzimidazol-2-ylidene **7**.

Dehydration of 1,3-diaryl-3-hydroxy-2-phenylpropan-1-ones **4a-e** with phosphorus pentoxide at 80 °C in benzene [12] gave good yields of 1,3-diaryl-2-phenyl-2-propen-1-ones **20a-e** as shown in Scheme 4.



Scheme 4 Dehydration of 1,3-diaryl-3-hydroxy-2-phenylpropan-1-ones **4a-e**

CONCLUSION

Treatment of aromatic aldehydes with benzyl halides in the presence of *N,N*-dimethylbenzimidazolium iodide in [bmim]OH at room temperature produced good yields of the corresponding 1,3-diaryl-3-hydroxy-2-phenylpropan-1-ones along with aroins and benzyl esters as minor side products. Mechanisms for the formation of 1,3-diaryl-3-hydroxy-2-phenylpropan-1-ones and benzyl esters are suggested. Dehydration of 1,3-diaryl-3-hydroxy-2-phenylpropan-1-ones using phosphorus pentoxide in benzene provided 1,3-diaryl-2-phenyl-2-propen-1-ones in good yields.

Acknowledgement

We gratefully acknowledge the Natural Products Research Unit, Department of Chemistry, Faculty of Science, Khon Kaen University, and the Center for Innovation in Chemistry (PERCH-CIC) and the Commission of Higher Education (CHE-RG), Ministry of Education for financial support.

REFERENCES

- [1] S. Arfaie, A. Zarghi, *Eur. J. Med. Chem.*, **2010**, 45, 4013-4017.
- [2] L. Lin, W. Du, W.-P. Deng, *Tetrahedron Lett.*, **2010**, 51, 3571-3574.
- [3] V. Hahnvanawong, B. Pungpis, P. Theramongkol, *ACGC Chem. Res. Comm.*, **2009**, 23, 26-30.
- [4] V. Hahnvanawong, W. Waengdongbung, S. Piekkaew, B. Phungpis, P. Theramongkol, *Scienceasia*, **2013**, 39, 50-55.
- [5] V. Hahnvanawong, W. Waengdongbung, P. Theramongkol, *Orient. J. Chem.*, **2016**, 32, 219-225.
- [6] B. Pungpis, V. Hahnvanawong, P. Theramongkol, *Orient. J. Chem.*, **2014**, 30, 933-939.
- [7] J.-M. Xu, B.-K. Lu, W.-B. Wu, C. Qian, Q. Wu, X.-F. Lin, *J. Org. Chem.* **2006**, 71, 3991- 3993.
- [8] B.C. Ranu, R. Jana, *Eur. J. Org. Chem.*, **2006**, 3767-3770.
- [9] B.C. Ranu, S. Banerjee, R. Jana, *Tetrahedron*, **2007**, 63, 776-782.
- [10] S.G. Patil, R.R. Bagul, M.S. Swami, S.N. Hallale, V.M. Kamble, *J. Chem. Pharm. Res.*, **2011**, 3, 457-463.
- [11] V. Hahnvanawong, R. Tearavarich, P. Theramongkol, *ACGC Chem. Res. Comm.*, **2005**, 18, 7-10.
- [12] J. Cermak, T.H. Nguyen Thi, A. Veelak Krupkova, *Molecules*, **2011**, 16, 4031-4044.